Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 27 studies | 51% ± 18% | |
macrophage | 25 studies | 42% ± 20% | |
endothelial cell | 8 studies | 32% ± 14% | |
capillary endothelial cell | 4 studies | 26% ± 12% | |
endothelial cell of sinusoid | 4 studies | 39% ± 28% | |
myeloid cell | 4 studies | 36% ± 8% | |
dendritic cell | 3 studies | 19% ± 0% | |
mononuclear phagocyte | 3 studies | 28% ± 5% | |
astrocyte | 3 studies | 34% ± 6% |
Insufficient scRNA-seq data for expression of LYVE1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 8913.10 | 258 / 258 | 87% | 44.93 | 200 / 230 |
lung | 98% | 5304.84 | 566 / 578 | 74% | 5.78 | 850 / 1155 |
breast | 97% | 6525.64 | 446 / 459 | 42% | 3.04 | 467 / 1118 |
thymus | 91% | 4037.74 | 591 / 653 | 47% | 2.81 | 283 / 605 |
kidney | 63% | 1782.20 | 56 / 89 | 74% | 12.88 | 666 / 901 |
intestine | 96% | 5153.87 | 925 / 966 | 37% | 3.08 | 193 / 527 |
bladder | 95% | 3661.57 | 20 / 21 | 37% | 4.99 | 187 / 504 |
esophagus | 80% | 3739.99 | 1161 / 1445 | 45% | 3.37 | 83 / 183 |
ovary | 67% | 1931.38 | 120 / 180 | 58% | 4.87 | 249 / 430 |
spleen | 100% | 13100.37 | 241 / 241 | 0% | 0 | 0 / 0 |
stomach | 52% | 2367.70 | 188 / 359 | 48% | 2.76 | 136 / 286 |
adipose | 99% | 13518.00 | 1196 / 1204 | 0% | 0 | 0 / 0 |
uterus | 68% | 1739.31 | 115 / 170 | 25% | 2.38 | 115 / 459 |
blood vessel | 89% | 3908.96 | 1191 / 1335 | 0% | 0 | 0 / 0 |
skin | 47% | 1148.58 | 842 / 1809 | 41% | 4.22 | 195 / 472 |
liver | 45% | 1161.91 | 101 / 226 | 43% | 3.66 | 173 / 406 |
brain | 6% | 87.70 | 169 / 2642 | 79% | 13.67 | 559 / 705 |
prostate | 44% | 929.62 | 107 / 245 | 35% | 1.50 | 175 / 502 |
pancreas | 12% | 157.94 | 40 / 328 | 65% | 6.40 | 116 / 178 |
heart | 62% | 1828.61 | 536 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 2.83 | 16 / 29 |
tonsil | 0% | 0 | 0 / 0 | 33% | 1.36 | 15 / 45 |
muscle | 29% | 486.66 | 232 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 21% | 1.34 | 17 / 80 |
peripheral blood | 8% | 271.69 | 76 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009611 | Biological process | response to wounding |
GO_0030214 | Biological process | hyaluronan catabolic process |
GO_0006898 | Biological process | receptor-mediated endocytosis |
GO_0002693 | Biological process | positive regulation of cellular extravasation |
GO_0007160 | Biological process | cell-matrix adhesion |
GO_0009653 | Biological process | anatomical structure morphogenesis |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0038024 | Molecular function | cargo receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0005540 | Molecular function | hyaluronic acid binding |
Gene name | LYVE1 |
Protein name | Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1) (Cell surface retention sequence-binding protein 1) (CRSBP-1) (Extracellular link domain-containing protein 1) (Hyaluronic acid receptor) Lymphatic vessel endothelial hyaluronan receptor 1 |
Synonyms | HAR UNQ230/PRO263 XLKD1 CRSBP1 |
Description | FUNCTION: Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes . Binds to pericelluar hyaluronan matrices deposited on the surface of leukocytes and facilitates cell adhesion and migration through lymphatic endothelium . . |
Accessions | E7EPC7 Q9Y5Y7 ENST00000438354.6 ENST00000529598.1 F2Z296 ENST00000256178.8 |